Abstract

Objective: To bring awareness to the ophthalmologist about the state of the discussion in relation to the issue regarding the phosphate content in the collyriums for ophthalmic use. In order to inform professionals so they could make an appropriate selection of the medicine to be prescribed.

Materials and Methods: Review of the composition of the eye drops market in the country and registry of the phosphate levels.

Data was retrieved from information provided by pharmaceutical companies and by Administración de Medicamentos, Alimentos y Tecnología Médica (ANMAT) [National Administration for Drugs, Food and Medical Technology] from the Argentine Republic.

Results: Through the analysis, it was seen that most collyrium which are marketed in our country have phosphate concentrations higher than the physiological lacrimal concentration (0.4 - 1.45 mmol/L).

Conclusion: In patients who present an alteration of the surface and/or ocular inflammation, the administration of drops with high levels of phosphate is implicated in the generation of calcium precipitation phenomena at the corneal level. The selection of eye drops which do not contain phosphates, or which contains them at physiological levels, might have a beneficial impact on the management of the patient.

Keywords: Eye Drops; Corneal Calcifications; ANMAT

References

1. Vishal Jhanji., et al. “Corneal calcific band keratopathy”. Current Opinion in Ophthalmology4 (2011): 283.
2. Bernauer W., et al. “Phosphate concentrations in antiglaucoma medication”. Klinische Monatsblätter für Augenheilkunde 4 (2007): 249-251.
3. Moisseiev E., et al. “Acute calcific band keratopathy: case report and literature review”. Journal of Cataract and Refractive Surgery 2 (2013): 292-294.
4. Galor A., et al. “Transient band keratopathy associated with ocular inflammation and systemic hypercalcemia”. Clinical Ophthalmology3 (2008): 645-647.
5. Bernauer W., et al. “Corneal calcification following intensified treatment with sodium hyaluronate artificial tears”. British Journal of Ophthalmology3 (2006): 285-288.
6. Norbert F Schrage., et al. “Changing the composition of buffered eye-drops prevents undesired side effects”. British Journal of Ophthalmology11 (2010): 1519.
7. S B Anderson., et al. “Corneal calcification after amniotic membrane transplantation”. British Journal of Ophthalmology5 (2003): 587-591.

Citation

Citation: D´Alessandro Leonardo P., et al. “Corneal Calcium Deposits: Phosphate ROL in Eye Drops". Acta Scientific Paediatrics 4.4 (2021): 66-72.

Copyright

Copyright: © 2020 D´Alessandro Leonardo P., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.